Virtually all patients (93%) experienced improvements in at least one BILAG B- or C-level disease activity at 6, 10 and 18 weeks
Virtually all patients (93%) experienced improvements in at least oneRead More
autophagy inhibitors for cancer chemotherapeutics
autophagy inhibitor
Virtually all patients (93%) experienced improvements in at least oneRead More